Drug Type Synthetic peptide |
Synonyms- |
Target |
Mechanism NR4A1 antagonists(Orphan nuclear hormone receptor NR4A1 antagonists), PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | CN | 29 Apr 2024 |